article thumbnail

FDA sends warning letter to KVK-Tech manufacturing facility

European Pharmaceutical Review

The document identified significant violations of current good manufacturing practice (cGMP) regulations for finished pharmaceuticals. Inadequate validation of test methods : KVK-Tech failed to establish and document the accuracy, sensitivity, specificity and reproducibility of test methods.

FDA 88
article thumbnail

STAT+: Pharmalittle: We’re reading about FDA guidance on AI, meds releasing ‘forever chemicals,’ and more

STAT

As of last October, the agency had received more than 500 drug submissions with AI components going back to 2016, with a large number in the areas of oncology, neurology, and gastroenterology.

FDA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A Temporary Extension for the Rare Pediatric Disease Priority Review Voucher with a Longer-Term Extension in Sight?

The FDA Law Blog

Although the program has not been without its critics (including as documented in two GAO reports from 2016 and 2020 ), there is ample evidence that the program has been successful at accomplishing its goals, which has become more evident with time. Notably, it was reauthorized in 2016 (until 2020) and in 2020 (until 2024).

article thumbnail

Can rare disease research in the US thrive under the new administration?

Pharmaceutical Technology

Comstock said it is not yet clear if the report will be turned into an official agency guidance document, but it will be made publicly available. However, the PRV program for rare pediatric diseases is at risk of expiry in September 2026, and is pending renewal.

FDA 52
article thumbnail

From data to impact: How real-world evidence will transform healthcare

pharmaphorum

Skip to main content Monday 7 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

Beyond instruments: streamlining process technology implementation in biopharmaceutical manufacturing

European Pharmaceutical Review

To give examples, such a work package focuses on the identification of regulations (ICH Q2 R2, 3 Q8-Q14, 4-10 FDA PAT guidance, 11 EMA Annex 15 12 ), some of which may be mainly guidance documents with recommendations and flexibility when it comes to PAT.

article thumbnail

FDA’s Vape Ban Hits the Right Note: Supreme Court Says “Let It Be”

The FDA Law Blog

This opinion, which overrules a Fifth Circuit decision that FDA had acted arbitrarily and capriciously in denying premarket tobacco product applications submitted by manufacturers of flavored e-liquids for open-system e-cigarettes, marks the latest development in the ongoing debate and FDA regulation of flavored vape products.

FDA 59